Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Zhejiang-based Zhejiang Shimai Pharmaceutical Co.,Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...
China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...
Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...
China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...